Rhovac | Chosa Oncology

News published before 1 May 2017 in Swedish only.

2022

Dec 05, 2022

RhoVac AB conducts conditional reverse takeover of Chosa ApS

Regulatory press release: RhoVac AB (“RhoVac or the “Company) has entered into an agreement to acquire all shares in the Danish privately owned oncolo...[Read more]

Oct 18, 2022

Rhovac board member resigns due to health reasons

Regulatory press release: RhoVac AB (publ) announces today, October 18[th] 2022, that board member and co-founder Anders Ljungqvist is resigning from...[Read more]

Aug 26, 2022

Board member Lars Hedbys takes over as acting CEO of RhoVac on 1 September

Regulatory press release: RhoVac AB (RhoVac) announces today, August 26[th] 2022, that the board has decided to appoint board member Lars Hedbys as ac...[Read more]

Aug 09, 2022

The board decides on first partial repayment of convertible loan

Regulatory press release: RhoVac AB (RhoVac), announces today, 9[th] August 2022, that the board has approved a first repayment of the convertible loa...[Read more]

Jul 15, 2022

RhoVac's CEO, Anders Månsson, has tendered his resignation

Regulatory press release: RhoVac AB (RhoVac), announces today, July 15 2022, that the companys CEO, Anders Månsson, has announced his wish to leave hi...[Read more]

Jul 13, 2022

RhoVac terminates its stock liquidity provision service and announces the last day for trading in the convertible

Regulatory press release: RhoVac AB (RhoVac), announces today that the company with effect from 13 July has terminated its agreement with Sedermera on...[Read more]

Jun 30, 2022

RhoVac provides a status update and investigates a potentially accelerated repayment of the convertible loan

Regulatory press release: RhoVac AB (RhoVac), (June 30[th] 2022) a Swedish company active in cancer immunotherapy, was forced on 29 May 2022 to announ...[Read more]

May 29, 2022

RhoVac’s phase IIb study in prostate cancer , BRaVac, failed to meet its primary endpoint

Regulatory press release: RhoVac AB (RhoVac), a Swedish cancer immunotherapy company, regrets to announce today on May 29th, 2022, that its phase IIb...[Read more]

May 18, 2022

Pre-clinical findings support the potential use of RhoVac’s drug candidate, onilcamotide, across several cancers

Regulatory press release: RhoVac AB (“RHOVAC) today, 18[th] May 2022, announces preclinical findings from its collaboration with St. John’s Research I...[Read more]

May 10, 2022

RhoVac AB announces Database Lock in its clinical phase IIb trial of onilcamotide

Regulatory press release: RhoVac AB (RhoVac), a Swedish cancer immunotherapy company, announces today on May 10th, 2022, that its phase IIb study in p...[Read more]

Feb 09, 2022

Complement: RhoVac plans for a fully guaranteed convertible loan rights issue, to finance activities following a successful clinical phase IIb study outcome

Regulatory press release: Complement: appendix added to previous release. RhoVac AB (RhoVac) announces today, February 9, 2022, that the Board of Dire...[Read more]

Feb 09, 2022

RhoVac plans for a fully guaranteed convertible loan rights issue, to finance activities following a successful clinical phase IIb study outcome

Regulatory press release: RhoVac AB (RhoVac) announces today, February 9, 2022, that the Board of Directors intends to decide on execution of a prefer...[Read more]

Jan 24, 2022

The Canadian Intellectual Property Office intends to grant RhoVac’s patent application for RV001 (onilcamotide) cancer vaccine

RhoVac AB (RhoVac) announces today, 24[th] January 2022, that the Canadian Intellectual Property Office (CIPO) has issued a...[Read more]